Advertisement
Advertisement
CING
Cingulate Inc. Common Stock
5.27
USDSponsored
+0.04
+0.76%
May 08, 16:00 UTC -4
Closed
After-Market
5.32
+0.05
+0.85%
CING Earnings Reports
Positive Surprise Ratio
CING beat 7 of 17 last estimates.
41%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Cingulate Inc. Common Stock earnings per share and revenue
On Mar 18, 2026, CING reported earnings of -0.93 USD per share (EPS) for Q4 25, missing the estimate of -0.64 USD, resulting in a -44.59% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -31.05% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
FAQ
What were Cingulate Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Cingulate Inc. Common Stock reported EPS of -$0.93, missing estimates by -44.59%, and revenue of $0.00, 0% as expectations.
How did the market react to Cingulate Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -31.05%, changed from $11.66 before the earnings release to $8.04 the day after.
When is Cingulate Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Cingulate Inc. Common Stock's next earnings report?
Based on --
analysts, Cingulate Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement